Involving Proteinase Patents (Class 435/23)
  • Patent number: 10788450
    Abstract: A preparation method for an aerolysin nanopore in this disclosure comprises the following steps: (1) pretreatment of an aerolysin; (2) preparation of a lipid bilayer membrane by pulling process; (3) forming of the aerolysin nanopore: the aerolysin nanopore is obtained at a current of 50±5 pA. The aerolysin nanopore prepared in the invention is structurally stable and has a high resolution with the whole internal cavity carried with a positive charge, can be used for detection without modification and is easily operated. Further, the aerolysin nanopore can be applied in DNA sequencing, DNA damage and Micro-RNA detection.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 29, 2020
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yitao Long, Chan Cao, Yongxu Hu
  • Patent number: 10626438
    Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: April 21, 2020
    Assignee: The Broad Institute, Inc.
    Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
  • Patent number: 10620223
    Abstract: Methods are provided for quantifying the fibroblast growth factor receptor 2 protein (FGFR2) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. The biological sample may be selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells. A protein sample is prepared from the biological sample and the FGFR2 protein is quantitated in the sample using the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one fragment peptide derived from FGFR2.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 14, 2020
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Patent number: 10578625
    Abstract: The present invention relates to the field of proteomics and more specifically to a method for analyzing a sample possible containing peptides or modified peptides; in particular useful for biomarker discovery or validation of biomarkers. The method uses isoelectric focusing and mass spectrometry (MS) and enables identification of modified peptides with high resolution and predictability.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: March 3, 2020
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Peter Mats Oliviusson, Janne Lehtio, Rui Miguel Mamede-Branca
  • Patent number: 10557857
    Abstract: Disclosed are embodiments of a lateral flow test strip (LFTS) platform which measure osteocalcin (OC) and deoxypyridinoline (Dpd) in saliva to identify early indications of bone loss and minimize bone fracture risk associated with osteoporosis. The OC assay embodiments are based on the experimentally identified optimal markers which exhibit selectivity with very low false positives, and sensitivity relevant to clinical requirements. A prospective clinical study sampling of 20 patients demonstrated excellent correlation of OC in saliva with bone mineral density (BMD). Salivary OC and Dpd levels were validated with a standard commercial ELISA kit against serum (OC) and urine (Dpd).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 11, 2020
    Assignee: Intelligent Optical Systems, Inc.
    Inventors: Manal Beshay, Morgan Hatch
  • Patent number: 10539566
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: January 21, 2020
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Vivek K. Vishnudas, Rangaprasad Sarangarajan, Viatcheslav R. Akmaev
  • Patent number: 10537663
    Abstract: A method for preparing a decellularized tissue-based hydrogel with maximized ability of preserving various tissue-derived proteins, growth factors and cytokines by using a supercritical fluid-organic solvent system through (a) a step of decellularizing a biological tissue by bringing the same to contact with a supercritical fluid and an organic solvent at the same time; (b) a step of washing the decellularized tissue; (c) a step of preparing a decellularized tissue solution by mixing the washed decellularized tissue with one selected from an enzyme solution, an acidic solution and a mixture thereof; (d) a step of titrating the decellularized tissue solution to pH 5.5-7.8 by treating with a basic solution; and (e) a step of allowing the titrated decellularized tissue solution to stand at 30-40° C. and utilizing the same as a tissue engineering material with improved angiogenesis and tissue regeneration abilities.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Korea Institute of Science and Technology
    Inventors: Young Mee Jung, Soo Hyun Kim, Yoo Jin Seo
  • Patent number: 10508135
    Abstract: Compositions and methods for analyzing protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity, using a cell based assay are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT. The fluorophores are positioned so that no useful FRET occurs between them, permitting fluorescence produced by the non-released fluorophore to be used in data normalization.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 17, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Patent number: 10428366
    Abstract: A method of measuring soluble or insoluble cell or tissue-associated collagenase activity. The substrate includes native collagen fibrils that were stained with COOMASSIE Brilliant Blue R-250. Incubation with collagenase can be observed in real-time by the generation of digested smaller fragments. The degraded blue fragments are obtained by filtration through class fibers, onto which intact collagen fibrils are retained. The filtrate containing the blue collagen fragments is incubated with a detergent in order to extract the blue dye, and the mixture is centrifuged in order to separate the dye in the supernatant from the pellet, which contains de-stained collagen fragments and other insoluble materials contained in the test samples (such as bacterial cells or tissues). The amount of dye extracted is quantified by measuring the amount of dye extracted from these fragments, i.e., the absorbance at 600 nm using a spectrophotometer or an ELISA reader.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 1, 2019
    Assignee: University of South Florida
    Inventor: My Lien Dao
  • Patent number: 10415024
    Abstract: The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: September 17, 2019
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Eric M. Ostertag, Tseten Yeshi
  • Patent number: 10416171
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 17, 2019
    Assignee: Seqirus UK Limited
    Inventors: Yingxia Wen, Ethan Settembre, Zihao Wang
  • Patent number: 10400263
    Abstract: The present invention concerns rhodamine based fluorescent probes which have use in detecting coagulase-producing bacterial strains. In particular, wherein the bacterial strain is MRSA or MSSA.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: September 3, 2019
    Assignee: Kingston University Higher Education Corporation
    Inventors: Alex Sinclair, Mark Fielder, Adam Le Gresley
  • Patent number: 10392646
    Abstract: The present invention relates to a biosensor capable of measuring the total concentration of one or a plurality of amino acids with the use of a reagentless system comprising an electrode modified by hydrogel that comprises at least one enzyme that oxidizes at least one substrate that is at least one amino acid. In some embodiments, the biosensor comprises a hydrogel comprising alginate. In some embodiments, the biosensor comprises use of a thermophilic bacterial metabolic enzyme immobilized or attached to the hydrogel.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 27, 2019
    Assignees: University of Maryland, College Park, Children's National Medical Center, The United States of America, as Represented by The Secretary, Department of Health and Human Services
    Inventors: Omar Bilal Ayyub, Adam Michael Behrens, Peter Kofinas, Marshall Lynn Summar, Juan Manuel Cabrera-Luque, Gary Cunningham, Anton Simeonov, Juan Marugan
  • Patent number: 10351817
    Abstract: This invention provides an Amycolatopsis sp. strain (zhp06), and a method of using the whole cell preparation of the strain for vanillin production. The strain was deposited in China Center for Type Culture Collection on Jul. 26, 2011 with the number of CCTCC NO: M 2011265. Under high concentrations of ferulic acid substrate, the vanillin production by this method can reach more than 10 g/L. The molar conversion rate of ferulic acid is more than 50% and the purity of vanillin is from 80% to 95%. The advantage of this invention includes: repeated use of biocatalyst cells, mild biotransformation condition, low environmental pollution, short production cycle, high product purity and simple purification procedure. It has a great potential for industrial applications.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 16, 2019
    Assignee: BGN TECH LLC
    Inventors: Pu Zheng, Hui Li, Xinglin Wang, Jianhai Zhou, Shibiao Chu
  • Patent number: 10328161
    Abstract: The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 25, 2019
    Assignee: The Regents of the University of California
    Inventors: Christopher J. Chang, Carolyn R. Bertozzi, Genevieve C. van de Bittner, Elena A. Dubikovskaya
  • Patent number: 10254280
    Abstract: The invention relates to a channel for trapping particles to be fed to the channel with a fluid. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates to a method for trapping particles in such a channel. And finally, the invention relates to a method for analyzing a sample using such an assembly.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 9, 2019
    Assignees: Micronit Microtechnologies B.V., Janssen Pharmaceutica NV, NXP B.V.
    Inventors: Marko Theodoor Blom, Monica Brivio, Simone Tanzi, Simon Reuvekamp, Bieke Van Dorst, Lieven Jozef Stuyver, Elfried Van Der Sar
  • Patent number: 10247711
    Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Promega Corporation
    Inventors: Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
  • Patent number: 10246492
    Abstract: Compositions and methods for analyzing intracellular BoNT protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 2, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Francis Mark Dunning
  • Patent number: 10202632
    Abstract: A method for determining the amount of glycated hemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are hemolyzed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated hemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 12, 2019
    Assignee: DiaSys Diagnostic Systems GmbH
    Inventors: Günther Gorka, Yoshifumi Watazu, Erwin Metzmann, Alexandra Lein, Holger Müller, Matthias Grimmler
  • Patent number: 10201896
    Abstract: A processing method is for performing a processing with respect to a processing object in at least one field among biochemistry, biology, and biotechnology. The processing method includes transferring, using at least one arm of a robot configured to perform the processing, a container to a mover with the processing object attached on an inner surface of the container. The processing object is moved, using the mover, to a predetermined position on the inner surface of the container. The processing is performed, using a pipette mounted on the arm, with respect to the processing object at the predetermined position.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 12, 2019
    Assignee: KABUSHIKI KAISHA YASKAWA DENKI
    Inventors: Eiji Kihara, Sakae Yamaguchi, Kohei Miyauchi
  • Patent number: 10197576
    Abstract: A method for the identification and localization of proteins or other biomolecules of a histologic tissue section comprises enzymatically digesting the biomolecules of two similar tissue sections while substantially preserving the biomolecule positions in the tissue sections. Next, a mass spectrometric image of the digest products in one of the tissue sections is acquired. Then, the digest products of the other tissue section are extracted and separated and the mass spectra and daughter ion spectra of all the digest products are acquired. A list of all identifiable biomolecules of the tissue section is created by comparing the mass spectra and daughter ion spectra with spectra in biomolecule structure databases or spectral libraries. Finally, the biomolecules in the list are assigned to digest products of the same mass in the mass spectra used to create the mass spectrometric image of the thin tissue section.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 5, 2019
    Inventors: Detlev Suckau, Martin Schürenberg, Rainer Paape, Christine Lübbert
  • Patent number: 10191051
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin in media having a reduced sodium concentration, thereby increasing the sensitivity. Such media can also be used in combination with elevated cell culture temperatures. Kits that include such media and a botulinum toxin are also described.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 29, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 10119969
    Abstract: The invention provides methods and compositions for the detection and/or quantification of a microbial contaminant, for example, a bacterial endotoxin or a glucan, in a sample. In particular, the invention provides a test cartridge useful in the practice of hemocyte lysate-based assays for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides methods of making and using such cartridges. In addition, the invention provides a rapid, sensitive, multi-step kinetic hemocyte lysate-based assay for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides a glucan-specific lysate that can be used in a variety of assay formats, including, for example, a test cartridge, optionally configured to perform a kinetic assay.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: November 6, 2018
    Assignee: Charles River Laboratories, Inc.
    Inventors: Norman R. Wainwright, Foster T. Jordan
  • Patent number: 10087190
    Abstract: The present disclosure relates to novel lactones such as dihydropyrrole-fused furanones, a novel palladium-catalyzed carbonylation method to make the novel lactones, and method of using the novel lactones as anti-fungal and/or anti-bacteria agents.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 2, 2018
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Mingji Dai, Mohamed Seleem, Xianglin Yin
  • Patent number: 10077285
    Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 18, 2018
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Clayton T. McKee, William Strong
  • Patent number: 10041961
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10024797
    Abstract: Herein disclosed are biosensing systems that measure lactose concentration in a solution.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: July 17, 2018
    Assignee: Colorado State University Research Foundation
    Inventors: Kenneth F. Reardon, David S. Dandy, Ryan E. Holcomb
  • Patent number: 10017879
    Abstract: Methods and compositions for generating mixtures of product molecules from an initial chemical array are provided. In the subject methods, a chemical array of surface immobilized first moieties is subjected to cleavage conditions such that a composition of solution phase first moieties is produced. The resultant composition of solution phase first moieties is then contacted with one or more reactants to produce a mixture of product molecules that are different from the first moieties. Also provided are the arrays employed in the subject methods and kits for practicing the subject methods.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: July 10, 2018
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Mel N. Kronick, Eric M. Leproust
  • Patent number: 9969992
    Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: May 15, 2018
    Assignee: Syngenta Participations AG
    Inventors: David P. Weiner, Ame I. Solbak, Jr., Ryan McCann
  • Patent number: 9944971
    Abstract: The present invention relates to a method for detecting at least one direct thrombin inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a thrombin inhibitor with a composition containing thrombin under conditions which allow the thrombin to release a detectable substance from a chromogenic substrate.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 17, 2018
    Assignee: DOASENSE GmbH
    Inventors: Job Harenberg, Roland Kramer
  • Patent number: 9938561
    Abstract: Provided is a method for diagnosing cancer through a difference with a control group in view of the ratio of a deglycosylated peptide fragment and a non-glycosylated peptide fragment in a protein including an N-linked glycosylation motif. Further provided is a method for diagnosing cancer through the detection of the glycosylation ratio in the protein according to the subject matter enables the diagnosis of cancer with high specificity and sensitivity using at least one existing marker, and can be useful in discovering new markers for diagnosing cancer.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 10, 2018
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Youngsoo Kim, Jung-Hwan Yoon, Hyunsoo Kim, Kyunggon Kim, Jonghwa Jin
  • Patent number: 9932622
    Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 3, 2018
    Assignee: Woundchek Laboratories B.V.
    Inventors: Simon William Bayliff, Breda Mary Cullen, Molly Gibson
  • Patent number: 9927438
    Abstract: The subject invention provides point-of-care assays for assessing the topographical distribution of microbial biofilm and/or specific microorganisms in wounds.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 27, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Gregory S. Schultz, Edith Marion Sampson, Priscilla Lorraine Phillips
  • Patent number: 9920306
    Abstract: Mutated ?-glucuronidase enzymes with enhanced enzymatic activity and thermostability as compared to wild type enzyme are provided. The enzymes of the invention advantageously allow for accurate analysis of bodily samples for the presence of drugs in 30 minutes or less, as compared to the several hours needed using prior enzyme preparations. Methods of using the mutated enzymes for hydrolysis of glucuronide substrates, including opiates and benzodiazepines, are also provided.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: March 20, 2018
    Assignee: INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, LLC
    Inventor: Lim Andrew Lee
  • Patent number: 9909111
    Abstract: Mutated Lactobacillus brevis strain 269Y ?-glucuronidase enzymes with enhanced enzymatic activity at low pH (e.g., below pH 6.8), as well as enhanced thermostability as compared to wild type enzyme are provided. The enzymes of the invention advantageously allow for accurate analysis of bodily samples for the presence of drugs at low pH and in 30 minutes or less, as compared to the several hours needed using prior enzyme preparations. Methods of using the mutated enzymes for hydrolysis of glucuronide substrates, including opiates and benzodiazepines, are also provided.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 6, 2018
    Assignee: INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS
    Inventors: Jia Yang, Gary Horvath, Pongkwan Sitasuwan, Margarita Marinova, Qian Wang, Lim Andrew Lee
  • Patent number: 9856509
    Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: January 2, 2018
    Assignee: The Broad Institute, Inc.
    Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
  • Patent number: 9718859
    Abstract: Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are converted to inhibitors of GSK-3 upon interacting with the enzyme's catalytic site and hence act as disease-selective inhibitors for treating conditions associated with increased activity and/or expression of GSK-3. Each of the disclosed peptides is independently of no more than 15 amino acid residues, and has an amino acid sequence which comprises a ZX1X2X3Z(p) recognition motif of GSK-3, wherein Z(p) is a phosphorylated serine or threonine residue; Z is a phosphorylatable serine or threonine residue, and each of X1, X2 and X3 is independently any amino acid, as defined in the specification. Further disclosed are methods of identifying a putative substrate-competitive peptide inhibitor of GSK-3 which are effected by computational modeling and screening.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 1, 2017
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Hagit Eldar-Finkelman, Miriam Eisenstein, Avital Licht-Murava
  • Patent number: 9719075
    Abstract: Mutated Staphylococcus sp. RLH1 ?-glucuronidase enzymes with enhanced enzymatic activity and thermostability as compared to wild type enzyme are provided. The enzymes of the invention advantageously allow for accurate analysis of bodily samples for the presence of drugs in 30 minutes or less, as compared to the several hours needed using prior enzyme preparations. Methods of using the mutated enzymes for hydrolysis of glucuronide substrates, including opiates and benzodiazepines, are also provided.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: August 1, 2017
    Assignee: INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS
    Inventor: Lim Andrew Lee
  • Patent number: 9720000
    Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 1, 2017
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Sathibalan Ponniah, George E Peoples, Catherine E Storrer, Michael Flora
  • Patent number: 9714260
    Abstract: [Problem] To provide: a compound resulting from substituting with a silicon atom the oxygen atom at position 10 of a xanthene ring site of a rhodamine of which amino groups at position 3 and position 6 have an asymmetrical structure; a method for producing the compound; and a fluorescent probe that uses the compound. [Solution] The compound represented by general formula (I) or a salt thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: July 25, 2017
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Tetsuo Nagano, Kenjiro Hanaoka, Takahiro Egawa, Yu Kushida, Koji Numasawa, Takuya Myochin, Wen Piao
  • Patent number: 9702869
    Abstract: The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: July 11, 2017
    Assignee: DEFINED DIAGNOSTICS, LLC
    Inventors: Paul Q Hu, Xiaofen Huang, Reid W Von Borstel
  • Patent number: 9684002
    Abstract: Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and/or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep/uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL/uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: June 20, 2017
    Assignees: INTRINSIC LIFESCIENCES LLC, AUSTIN HEALTH
    Inventors: Mark E. Westerman, Rinaldo Bellomo, John Prowle, Michael Brownstein
  • Patent number: 9677114
    Abstract: Disclosed is a reverse-phase high-performance liquid chromatography based method for evaluating degradation pathways for panctreatin active pharmaceutical ingredients.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: June 13, 2017
    Assignee: Scientific Protein Laboratories, LLC
    Inventors: Anisha Akula, Yan Wang
  • Patent number: 9677063
    Abstract: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease inhibitor is useful as an anti-malarial agent acting on Plasmodium species, for example, Plasmodium vivax; and a method of identifying the activity of VX-4, are provided.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 13, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yoon Kong, Byoung-Kuk Na, Seon-Hee Kim, Young-An Bae
  • Patent number: 9636423
    Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: May 2, 2017
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy
  • Patent number: 9632097
    Abstract: The present embodiments relate to methods for determining or detecting pathological cartilage turnover by detection of Cartilage Oligomeric Matrix Protein (COMP) neoepitopes, both released into body fluids and present in the tissue. Furthermore the embodiments relate to antibodies against COMP neoepitopes and to fragments and peptides containing COMP neoepitopes for generation of such antibody.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: April 25, 2017
    Assignee: Nordic Boiscience A/S
    Inventors: Pilar Lorenzo, Patrik Önnerfjord, Emma Åhrman, Dick Heinegård
  • Patent number: 9632086
    Abstract: A method and kit for determining antibody sensitivity and quality of a clone cell stain. The method comprises: obtaining a solid-phase carrier, cells and an antibody; adsorbing the antibody on the solid-phase carrier; incubating the cells and the antibody; preserving cells bound with the antibody; and dyeing and counting the cells bound with the antibody, so as to determine the antibody sensitivity or the quality of the clone cell stain based on the cell count. The kit comprises components used in the method.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: April 25, 2017
    Assignee: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    Inventors: Yumei Zhao, Lifang Dong, Ting Lei
  • Patent number: 9598718
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 21, 2017
    Assignee: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christoph Posch, Hansjorg Toll, Robert Mayer
  • Patent number: 9580740
    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: February 28, 2017
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
  • Patent number: 9575065
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 21, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang